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Summary The V79/AP4 Chinese hamster fibroblasts were densely stained with the anti-basic fibroblast
growth factor (bFGF) antibody demonstrating an endogenous production of the peptide. The in vitro
proliferation of these cells was stimulated by exogenous bFGF and the maximum growth (259% increase in
3H-thymidine incorporation into DNA) was reached with bFGF 1Ong ml-'. Inhibition of bFGF-mediated
mitogenic pathway was obtained with a 15-mer antisense oligodeoxynucleotide targeted against bFGF mRNA
and with suramin, a drug which blocks the biological activity of heparin-binding growth factors. bFGF
antisense oligomer reduced the synthesis of DNA by 79.5 and 89.5% at 20 and 60 jtM, respectively; this effect
was reversed by the addition of exogenous bFGF to the culture medium. A short-term exposure to suramin
300 gg ml-' produced a modest reduction in 3H-thymidine incorporation but suppressed the mitogenic effect
of bFGF on V79/AP4 cells. In cells treated with suramin 300 gig ml- 'the drug concentration increased linearly
over 3 days, reaching 13.15 gg mg-' of protein; cell proliferation was inhibited in a dose-related manner as
evaluated by the colony formation assay (IC50: 344.22pgml-') and by the number of mitoses observed in
culture. Furthermore, the drug induced ultrastructural alterations, consisting of perinuclear cisternae swelling,
chromatin condensation, nucleolar segregation and cytoplasmic vacuolations. These findings demonstrated
that the endogenous production of bFGF plays an important role in V79/AP4 fibroblasts proliferation, and
the inhibition of bFGF-mediated mitogenic signalling with bFGF antisense oligomer or suramin is an effective
mean of reducing cell growth.
The possible involvement of growth factors in the regulation
of cancer cell proliferation has recently received major
emphasis (Aaronson, 1991). Basic fibroblast growth factor
(bFGF) is a powerful mitogen for several cell types and
bFGF mRNA transcripts have been found in normal and
malignant cells such as fibroblasts (Sternfeld et al., 1988),
mammary epithelium (Li & Shipley, 1991), epatoma (Abraham
et al., 1986) and rhabdomyosarcoma cells (Schweigerer et al.,
1987). bFGF modulates the in vitro growth and function of
mesenchymal cells, acting as a potent mitogen for a large
number of murine fibroblast cell lines including rat
fibroblast-1, BALB/c 3T3, Swiss 3T3 and BHK-21 cells (for
review see Gospodarowicz et al., 1987; Rifkin & Moscatelli,
1989).
The V79/AP4 cell line was originated from the V79
Chinese hamster lung cells (Simi et al., 1988); its growth rate
in culture is proportional to the number ofcells seeded and is
reduced when the culture medium is replaced 24 h after
plating with non-conditioned medium (Bernardini, unpub-
lished data): these findings support the possible involvement
of a growth factor-stimulated proliferation of V79/AP4
fibroblasts.
Modulation of cell growth by disruption of an autocrine
loop has recently been made possible by the introduction of
suramin, a hexasulfated naphthylurea initially used for the
treatment of parasitic diseases (Hawking, 1978) and years
later, in view of the suppression of reverse transcriptase
activity (De Clercq, 1979), for the treatment ofAIDS (Levine
et al., 1986). The drug is capable of displacing heparin-
binding growth factors, including bFGF, from their specific
cell receptors (for review see La Rocca et al., 1990a), inter-
rupting paracrine and possibly autocrine growth factor loops
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crucial to neoplastic proliferation. Subsequent studies showed
that suramin was active in the treatment of several metastatic
tumours (Stein et al., 1989) including adrenal (La Rocca et
al., 1990b) and prostate cancer (Myers et al., 1992).
On the basis of the effects displayed by suramin on growth
factor function, the present study investigated the effect of
the drug on the in vitro basal and bFGF-stimulated growth
and on the morphology of V79/AP4 Chinese hamster fibro-
blasts; furthermore, the cellular production of bFGF and the
effect of bFGF antisense oligomer on cell proliferation were
documented.
Materials and methods
Materials
Suramin was obtained from Bayer (Milano, Italy); the drug
was dissolved in sterile distilled water and protected from the
light until its use. Cell culture media and reagents with their
respective sources in parentheses were: bFGF (R&D Systems,
Minneapolis, MN, USA); 3H-thymidine (74.0 GBq mmol ',
37.0 MBq ml-', NEN-Dupont, Bad Homburg, Germany);
bovine serum albumin fraction V, phosphate buffered saline
(PBS), Dulbecco's modified Eagle's medium (DMEM), foetal
calf serum (FCS), antibiotics (penicillin, streptomycin),
0.05% trypsin and 0.02% EDTA in Ca++/Mg++-free Hank's
balanced salt solution and anti-bFGF immunoglobulins
(product no. F-3393) (Sigma Chem. Co., St. Louis, MO,
USA); unconjugated secondary antibody (swine anti-rabbit
immunoglobulins, lot no. 037) and the rabbit peroxidase-
antiperoxidase (PAP) complex (lot no. 040) (Dakopatts,
Glostrup, Denmark); diaminobenzidine (Fluka, Buchs, Swit-
zerland). Other chemicals were of analytical grade. Plastics
for cell culture was from Nunc (Roskilde, Denmark).
Cell cultures
The Chinese hamster fibroblast V79/AP4 cell line was main-
tained as monolayer cultures as previously described (Simi et
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al., 1988). Complete medium for cell culture was DMEM,
supplemented with 5% FCS, and antibiotics (penicillin
100 IU ml', streptomycin 100 tg ml-'). In these conditions,
cell doubling time was approximately 12 h. Cultures in
exponential growth phase were harvested with trypsin-EDTA
and cell number was determined using a particle counter
(Model ZF, Coulter Electronics Ltd., Luton, England).
Immunostaining ofbFGF
Cells were grown on sterile slides and 24 h after seeding they
were fixed at 4°C for 15 min with Carnoy's solution. The
endogenous peroxidase activity was blocked with 0.3% hyd-
rogen peroxide in methanol for 15 min and the nonspecific
protein binding was eliminated by treatment with 3% FCS
for 15 min. Incubation with anti-bFGF (1:20-1:1000) was
carried out in a humidified chamber at 4°C for 23 h and at
37C for 1 h; samples were sequentially incubated in swine
anti-rabbit immunoglobulins (1:50) for 30 min, in rabbit PAP
(1:100) for 30 min, and finally treated with 0.5 mg ml1'
diaminobenzidine containing 0.1% H202 for 10min. Control
samples were obtained by omitting the first antibody. The
solution used for rinsing between each step and for antibody
and diaminobenzidine dilution was 0.01 M PBS (pH 7.2).
Effect ofbFGF antisense oligomer on cellproliferation
bFGF antisense (5'-GGC-TGC-CAT-GGT-CCC-3') and ran-
dom (5'-CCG-TCG-GTA-CCC-GGT-3', Becker et al., 1989)
unmodified oligodeoxynucleotides were synthesised on
a multiple-column, automated DNA synthesiser (Millipore,
Milford, MA, USA), and were purified by HPLC. Concen-
trations of oligodeoxynucleotides were determined by absor-
bance at 260 nm, taking into account the molar extinction
coefficient of the nucleotides present in each sequence. These
small synthetic oligomers penetrate cells without any treat-
ment (Loke et al., 1989), react with their corresponding
mRNAs, and probably accelerate degradation of the specific
mRNA resulting in a reduction in the amount of specific
protein produced. The random sequence was used as a con-
trol.
The effect of oligomers on V79/AP4 cell proliferation was
evaluated on cells (2.5 x 102 cells/well in a 96-well plate) in
exponential growth phase treated with the oligodeoxynucleo-
tides for 22 h at a concentration of 20 or 60 tLM. Reversibility
of antisense bFGF oligomer growth inhibition was evaluated
on cells treated with bFGF 10ng ml-' and antisense bFGF
oligodeoxynucleotide 20 ILM for 22 h. Twenty-two hours
thereafter, cells were pulsed for 2 h with 1 I.Ci ml-' of 3H-
thymidine; to terminate the reaction, they were washed twice
with ice-cold PBS, extracted with 10% (w/v) cold tri-
chloroacetic acid and lysed with 0.25 N NaOH containing
4 mg 100 ml-' of salmon sperm DNA. Radioactivity was
measured by resuspending 0.5 ml of the cell lysate in 10 ml of
Riatron liquid scintillation fluid and counted with a Beta-
matic V P-counter (Kontron Instruments, Milano, Italy).
Cellular concentration ofsuramin
V79/AP4 cells were plated at a density of 1.2 x 104 cells cm-2
in 25cm2 flasks containing serum-supplemented culture
medium and suramin 300 pg ml-' was added once after 24 h.
Culture medium was aspirated 24, 48, and 72 h later, cen-
trifuged at 1,500 g and stored at - 20C until assayed; the
cell monolayer was washed thrice with ice-cold PBS, and
then harvested with a cell scraper. Cells were resuspended in
1 ml of PBS, sonicated and stored att-t20°C. At the time of
the assay, 50 LIl of culture medium and 50 ,il of cell
homogenate were analysed for suramin concentration using a
reverse-phase, ion-paring HPLC method (Supko & Malspeis,
1990) and a Gilson HPLC system (Gilson, Villiers le Bel,
France). Cellular levels of suramin were expressed as .Lg of
the drug mg-' of total protein which was measured in cell
homogenate according to Lowry et al. (1951) using a Uvikon
930 spectrophotometer (Kontron Instruments, Milano, Italy).
Non-specific binding of suramin to the plasma membrane
was determined in cells exposed to the drug for 1 min; then
they were washed and the amount of drug bound to cells was
measured as reported above. The degree of albumin and
serum binding of suramin was determined with the Centricon
3 (molecular weight cutoff: 3,000 Da) centrifugal micro-
concentrators (Amicon, Danvers, MA, USA) following the
manufacturer's instructions; equivalent amounts of suramin
and albumin or serum proteins were mixed and loaded in the
tubes.
Colonyformation assay
V79/AP4 fibroblasts were seeded at 1.5 x 102 cells/well in
9.6 cm2 tissue culture dishes with 5 ml of complete medium;
suramin was added once at increasing concentrations. Treat-
ment with the drug was started after 24 h to allow cells to
recover from trypsinisation; during this time their pro-
liferative activity is negligible and the estimated doubling
time exceeds 24 h. After 72 h in the presence of the drug cells
were washed twice with PBS and fresh medium was added.
Ninety-six hours thereafter, plates were fixed with acetone
and methanol (1/1, v/v), stained with 1% methylene blue,
and colonies with more than 50 cells were scored as survivors
and counted. Experiments were performed in triplicate and
repeated thrice. The survival was expressed as the percentage
ratio of the colony-forming efficiency of treated cells com-
pared to controls and the drug concentration which inhibits
50% of the colony formation (IC50) was determined using
mathematical transformation in which the log of the fraction
of affected cells divided by the fraction of unaffected cells
was plotted vs the log of the drug concentration; the resulting
equation obtained with linear regression analysis was then
solved to determine the log of the IC50. The diameter of the
colonies was also evaluated using a graduated eyepiece.
Light and electron microscopy ofsuramin-treated cells
V79/AP4 fibroblasts were processed for light microscopy as
previously described (Bernardini et al., 1991) with minor
modifications. Briefly, cells were grown on sterile cover slides
and then treated once with graded concentrations of suramin
for 72 h. Ninety-six hours thereafter, slides were fixed with
acetone and methanol (1/1, v/v/), processed for haematoxylin
and eosin (H&E) staining and cellular alterations induced by
suramin were observed. Mitotic index was determined by
counting mitoses in stained cultures as a proportion of the
whole population (Freshney, 1987), using a 10 x squared
grid eyepiece and a 40 x objective.
Cells for electron microscopy were plated in 75 cm2 flasks
and incubated for 24 h. Suramin (150-600p.gml-') was
added once and 72 h later cultures were trypsinised and
centrifuged twice to obtain a cell pellet, which was processed
for electron microscopy as previously reported (Bernardini et
al., 1991). Briefly, cells were fixed at 4°C for 2 h in 2.5%
glutaraldehyde and 4% paraformaldehyde buffered solution
(pH 7.2), and postfixed in 1% osmium tetroxide for 1 h.
After dehydration in graded ethanol solutions, the cells were
embedded in Epon and sectioned by an Ultrotome Nova
LKB (LKB Bromma, Sweden) ultramicrotome. Sections were
stained with 5% uranyl acetate in 50% ethanol and with lead
citrate and observed with an Elmiskope 101 Siemens (Ger-
many) electron microscope.
Suramin-bFGF interaction
Stimulation of 3H-thymidine uptake into quiescent V79/AP4
cells by bFGF was measured as follows. Fibroblasts (6 x 103
cells) were plated in 24-well plates in complete medium; when
they were at confluence, medium was removed, cells washed
once with DMEM, and medium replaced with serum-free
DMEM containing BSA 0.4 mg 100 ml1' and suramin 300jig
ml1'. Two hours later bFGF (0.1, 1, 10, and 50 ngml-') was
added once and cells incubated for additional 2 h. Control
cultures were treated with either suramin or bFGF. Pulse-EFFECT OF BFGF AND SURAMIN ON V79/AP4 CELL GROWTH 1211
labelling of cells with 1 ACi ml-' of 3H-thymidine and
measurement ofincorporated radioactivity were performed as
reported above.
Results
Immunostaining ofbFGF
The nuclei of V79/AP4 cells fixed with Carnoy's solution
were densely stained with the anti-bFGF antibody while a
faint immunoreaction was observed in the cytoplasm of
fibroblasts (Figure la). The reaction was specific since cont-
rol preparations, obtained by omitting the first antibody, did
not show any substantial reactivity (Figure lb). Similar
results were obtained when cells were fixed with acetone-
methanol (1:1, v:v) or acetone alone.
Effect ofbFGF antisense oligomer on cellproliferation
The V79/AP4 cell growth was reduced by bFGF 15-mer
antisense oligomer targeted against bFGF mRNA: a - 79.5
and - 89.5% inhibition of cell proliferation was obtained
with 20 and 601M respectively, while random sequence
oligomer was without effect (Figure 2). The addition of
bFGF to cells treated with the antisense oligomer markedly
reduced its inhibitory activity (Figure 2), indicating that the
effect was specific and reverted by the specific mitogen.
Cellular concentration ofsuramin
Drug concentration in both cell culture media and cells was
measured at various time points after treatment with
300 ,sg ml-' suramin. In cells treated for 1 min the cell-
associated amount of suramin was found to be 0.80iLgmg-'
of protein but it increased linearly up to the 72nd h reaching
13.15 ytgmg-' of protein (Figure 3). The mean suramin con-
centration in serum-supplemented culture medium was
225.31 tg ml-1 and the percentage of the drug bound to
serum proteins was 98.7%, a value which is very close to that
observed with serum albumin (99.3%).
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Figure 2 Effect of random (Rd) and antisense (As) bFGF oligo-
mer on DNA synthesis of V79/AP4 fibroblasts. Cells (2.5 x 102)
in exponential growth phase were treated for 22 h with the
oligomers and then pulsed for 2 h with 3H-thymidine and the
amount of incorporated label were determined. The effect of a
concomitant exposure of cells to antisense oligomer 20 luM and
bFGF 10 ng ml-' is also shown. Columns: mean of three
experiments, each performed in triplicate; bars: s.e.m.
Colonyformation assay
The cloning efficiency of V79/AP4 fibroblasts was evaluated
in a range of drug concentrations between 75 and 600Ag
b c
Figure 1 bFGF immunostaining in V79/AP4 cells, x 510. Fibroblasts are stained with anti-bFGF antibody (1:20) (a), as described
in the text: the endogenous bFGF is localised in the nucleus while very low amounts were found in the cytoplasm; control cells,
obtained by omitting the first antibody, were negative (b). Control fibroblasts stained with H&E, (c).1212 N. BERNARDINI et al.
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Figure 3 Cellular concentration of suramin in V79/AP4 cell line
and cellular protein content following exposure to suramin
300 Lgml' for 1 min, 24, 48, and 72h. Cells (1.2 x 104
cells cm-2) were treated with suramin 24 h after seeding. At the
aforementioned time points culture medium and cell homogenates
were assayed for suramin by a specific HPLC method; proteins
were determined spectrophotometrically with folin phenol re-
agent. The results are expressed as fig of suramin mg-' of total
proteins. Points: mean of three experiments; bars: s.e.m.
ml-. After a 72-h exposure to a single dose of suramin, the
colony-forming ability of the cell line was inhibited in a
dose-dependent manner (Figure 4) and the mean ICM, was
344.22ILg ml-'. Furthermore, the same treatment schedule
dose-dependently reduced the dimension of clones as
measured 96 h after the end of drug exposure (Figure 4).
Light and electron microscopy ofsuramin-treated cells
V79/AP4 fibroblasts observed by light microscopy are
spindle-shaped cells with many cellular processes and an oval
nucleus with one or more nucleoli. The histological pattern
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Figure 4 Effect of suramin on the colony formation assay and
the colony diameter of V79/AP4 cells plated in 6-well tissue
culture dishes (1.5 x 102 cells/well) and incubated with or without
suramin for 72 h. The survival was expressed as the percentage of
the cloning efficiency of treated cells vs control cultures. The
diameter (mm) of colonies was determined using a graduated
eyepiece; 30 clones from each well were examined. Points: mean
of three experiments, each performed in triplicate; bars: s.e.m.
observed after suramin treatment, even at the highest doses,
did not show any significant change compared with controls,
except for a decrease in the number of cells undergoing
mitosis, as shown by the mitotic index (Table I).
V79/AP4 cells prepared for electron microscopy appeared
round-shaped, with numerous irregular microvilli; their
nuclei showed small indentations of the borders with one or
more nucleoli. Numerous mithocondria, free ribosomes,
endoplasmic reticulum, vesicles and vacuoles with electro-
dense granular material were present in the cytoplasm
(Figure 5). Suramin-treated V79/AP4 fibroblasts showed
ultrastructural changes affecting both the cytoplasm and the
nucleus (Figure 6a); the frequency and severity of them did
Figure 5 Control V79/AP4 fibroblasts: Karnovsky, osmium tetroxide, Epon, uranil acetate, lead citrate, x 5800. The nucleus is
round-shaped with an indented border. Mitochondria, free and reticulum-linked ribosomes are contained in the cytoplasm. Vesicles
containing electrodense granular material are also present.
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Table I Mitotic indexa calculated in cell cultures treated once with
suramin for 72 h and observed 96 h after the end of treatment
Cells undergoing
Total cells mitosis Mitotic index
Controls 239 23 9.62
Suramin 150 mgml 349 16 4.58
Suramin 300 mgml 398 14 3.52
Suramin 600mgml-' 336 10 2.98
aMitotic indexwasdetermined bycountingmitosesinstainedcultures
as a proportion of the whole population (Freshney, 1987).
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Figure 6 Suramin-treated V79/AP4 fibroblasts: Karnowsky, osmium tetroxide, Epon, uranil acetate, lead cytrate. a, Panoramic
view, x 2800. b, Irregular nuclear borders, swelling of the perinuclear cisternae, chromatin addensation and nucleolar segregation
are present, x 3100. c, The cytoplasm appears fragmented because of the presence of faintly electrodense material, x 3100. d, A
large vesicle contains marked electrondense material; some endoplasmic reticulum vesicles are markedly swollen, x 3100. e,
Lengthened, widely spread vesicles appear in the endoplasmic reticulum, x 3100.1214 N. BERNARDINI et al.
not appear to be dose-related. Nuclear borders were more
irregular than those observed in control cells and well
marked by a swelling of the perinuclear cisternae; chromatin
condensation and nucleolar segregation were frequently pres-
ent (Figure 6b). A faint electrodense area surrounding
polyribosomes and/or mitochondria gave a fragmented
appearance to the cytoplasm (Figure 6c). Cytoplasmic
vacuoles were larger and more numerous than those of con-
trol cells and endowed with electrodense material (Figure 6d);
furthermore, the endoplasmic reticulum of treated fibroblasts
showed many lengthened vesicles (Figure 6e).
Suramin-bFGF interaction
The V79/AP4 cell line was stimulated by the addition of
bFGF (0.1, 1 and 1Ongml-') in a dose-dependent manner,
as indicated by the increase in 3H-thymidine incorporation
into DNA, reaching values up to 259% over control values.
The mitogenic effect was markedly inhibited by treatment
with suramin 300tLg mlh- (Figure 7); however, suramin alone
induced a modest reduction (- 18%) in 3H-thymidine
uptake.
Discussion
In view of the demonstrated relationship between growth
factors and tumour proliferation (Aaronson, 1991), new
therapeutic strategies have been conceived to control the
neoplastic growth by blocking the biologic activity of these
mitogenic peptides. Suramin is a candidate drug for inhibi-
tion of heparin-binding growth factor activity, particularly of
bFGF, with the result of interrupting autocrine and para-
crine loops crucial for tumour growth (La Rocca et al.,
1990a). It should be pointed out, however, that besides its
unique property of blocking the binding of growth factors to
their specific cell receptors, the drug induces a wide array of
biochemical modifications in living cells which lead to
impairment of cell survival and death. Suramin inhibits the
activity of protein kinase C, phosphatidylinositol and
diacylglycerol kinases (Mahoney et al., 1990; Kopp &
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Figure 7 Effect of suramin on bFGF-stimulated DNA synthesis
in V79/AP4 fibroblasts. Cells in serum-free culture medium were
sequentially treated with suramin 300 jg ml-' and with varying
concentrations of bFGF 2 h after suramin; 22 h later cells were
pulsed with 3H-thymidine and the DNA synthesis was determined
as the amount of incorporated label. In these experiments
suramin alone reduced 3H-thymidine uptake by 18%. Points:
mean of three experiments, each performed in triplicate; bars:
s.e.m.
Pfeiffer, 1990), and of several nuclear enzymes including
terminal deoxynucleotidyltransferase (Spigelman et al., 1987),
DNA and RNA polimerases (Jindal et al., 1990), and DNA
topoisomerase II (Bojanowski et al., 1992). For these reasons
the effect on cell proliferation is the result of the complex
interactions of drug-induced alterations, whose relative
importance may vary depending on the cell line and the
experimental conditions adopted.
In order to demonstrate the production of endogenous
bFGF in the cell line used in this study, immunostaining of
V79/AP4 fibroblasts was performed using an anti-bFGF
antibody. The histochemical data demonstrate a strong
immunoreactivity due to the presence of substantial amounts
of endogenous bFGF in the cell nucleus. This localisation
was also observed by Dell'Era et al. (1991) in normal and
transformed endothelial cells. This finding suggest that these
fibroblasts can proliferate without exogenous bFGF because
of their ability to produce and to respond to their own
growth factor. Furthermore, exogenous bFGF was demon-
strated to be able in vitro to enter the cell and translocate to
the nucleus, where it takes part in the activation of ribosomal
RNA transcription (Bouche et al., 1987; Baldin et al., 1990).
In addition to this, the growth of V79/AP4 fibroblasts was
markedly inhibited by a single treatment with 20 and 60tLM
of bFGF antisense oligomer, taken together, these findings
suggest that bFGF gene activation is crucial to drive cell
proliferation and endogenous bFGF may play an autocrine
activity in the in vitro growth of V79/AP4 fibroblasts. This
concept implies that cells could become malignant by the
endogenous production of polypeptide growth factors acting
on their producer cells via functional receptors, thus allowing
phenotipic response to the peptide by the same cell that
produced it. Our data extend previously reported observa-
tions on the autocrine stimulation by different growth factors
on various cell systems such as HT-29 human colon car-
cinoma (Culouscou et al., 1987), transformed NIH 3T3
fibroblasts (Moscatelli & Quarto, 1989), and SSV (simian
sarcoma virus-transformed)-NRK cells (Hicks et al., 1989).
During the 72 h-exposure to suramin the drug slowly
penetrated the V79/AP4 fibroblasts. The gradual intracellular
penetration of this anionic compound, might partially
account for the delayed growth-inhibitory effect observed by
others (Fantini et al., 1989; La Rocca et al., 1990b) following
exposure to suramin. The measurement of drug concentra-
tion in cells exposed to suramin for a very short period of
time, demonstrate that a modest quantity of the drug is
bound to the external surface of the plasma membrane; this
amount may be relevant to explain the rapid inhibition of the
biologic activity of bFGF added to the cell culture medium.
Quiescent VP79/AP4 fibroblasts were responsive to the
mitogenic activity ofexogenous bFGF and a marked increase
in 3H-thymidine incorporation was observed, in agreement
with previous data obtained in different fibroblast cell lines
(Gospodarowicz et al., 1987). In the present study suramin
impaired the colony forming ability of VP79/AP4 cells after
72-h exposure to the drug; the value of the IC50 was close to
the therapeutic range of plasma concentrations (250-300 fig
ml-') in animals and humans (La Rocca et al., 1990a). A
similar cell growth inhibitory effect was recently demon-
strated in several cancer cells whose proliferation is
modulated by growth factors (Fantini et al., 1989; La Rocca
et al., 1990c; Culouscou et al., 1988; Fantini et al., 1990). The
inhibitory effect displayed by suramin on V79/AP4 cell pro-
liferation was confirmed by the reduction of the number of
mitoses, the only histological change observed by light micro-
scopy after drug exposure. On the other hand, suramin
induced several ultrastructural changes both in the nucleus
and cytoplasm of V79/AP4 fibroblasts such as nucleolar
segregation, chromatin addensation and cytoplasmic vacuola-
tions; however, these morphological alterations were not
dose-related. In 3H-thymidine uptake experiments, suramin
alone produced a modest reduction in labelled DNA precur-
sor incorporation (- 18% vs controls), while the drug
effectively suppressed bFGF-induced cell growth; these
findings could be interpreted by assuming that after 24h r**X*XEFFECT OF BFGF AND SURAMIN ON V79/AP4 CELL GROWTH 1215
intracellular concentrations are too low to display direct
growth inhibitory effect but exogenously added bFGF is
complexed by suramin and its biologic activity suppressed.
Most of the pharmacodynamic properties of suramin are
dependent on the presence of six sulfonic groups on the
molecule itself which are able to bind to and inactivate
several cations, included growth factors and enzymes. For
the same reasons, other negatively charged molecules, such as
oligodeoxynucleotides, can work by an aptomer mechanism,
which may be at least partly responsible for the minor reduc-
tion in 3H-thymidine incorporation observed in the present
study following treatment with random oligomer. However,
the evidence that exogenous bFGF retains its stimulatory
activity on cells in culture in the presence of the antisense
oligomer and the almost complete lack of activity of the
random sequence suggest that in our experimental system the
aptomer mechanism is not responsible for the biological
activity of the antisense oligomer which is not endowed with
non-specific toxicity, as also demonstrated by others (Becker
et al., 1989). Even though the reduction in cellular produc-
tion of bFGF was not demonstrated in the present study, the
antiproliferative activity of the antisense oligomer seemed to
be specific since the random sequence and other molecules
(i.e. anti-PDGF) were without effect.
In conclusion, the data of the present study demonstrate
that V79/AP4 cell growth is stimulated by bFGF and
interventions which modify bFGF gene expression (i.e.
antisense oligomers) or block the biologic activity of bFGF
(i.e. suramin) reduce V79/AP4 proliferation. Even if the
antiproliferative effect of suramin is the result of the com-
bination of various effects, it may be concluded that the
disruption of a bFGF-mediated mitogenic pathway play a
relevant role in suramin's inhibition of cell growth.
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